Tiffany Lucas, MD
As a faculty member at UCSF Pediatric Hematology/Oncology, I see patients with pediatric hematologic and oncologic disorders although the majority of my time is spent in hematologic diseases such as patients with bleeding disorders, thromboses, immune cytopenias or aplastic anemia, bone marrow failure syndromes, and more. My research and academic focus is on quality improvement practices, patient safety, and medical education and I also do ongoing work in global health with the Commonwealth of the Northern Mariana Islands.
2019 - Diversity, Equity, and Inclusion Champion Training, University of California
Pediatric Hematology/Oncology Fellowship, 06/2016 - , University of California San Francisco
Pediatrics Residency, 2012 - , Children's Hospital of Philadelphia, University of Pennsylvania
MD, Global Health Track, 2009 - , Baylor College of Medicine
BS, Biochemistry and Cell Biology, 2005 - , Rice University
Honors and Awards
- American Society of Pediatric Hematology/Oncology (ASPHO) Clinician Educator Award, 2018
- American Society of Hematology Medical Educator's Institute Inductee, 2017
- Nancy Elizabeth Barnhart Award for dedication to children in the community, Children's Hospital of Philadelphia, 2012
- Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders.
- Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage.
- Frequency of face touching with and without a mask in pediatric hematology/oncology health care professionals.
- Investigation of Pediatric Anemia in the Commonwealth of the Northern Mariana Islands.
- Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.
- Understanding the evolving phenotype of vascular complications in telomere biology disorders.
- Comprehensive Review of Preschool Age Anemia in the Pacific Island Jurisdictions.
- The arc of fellowship.
- Capacity Building for Rare Bleeding Disorders in the Remote Commonwealth of the Northern Mariana Islands.
- Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality.
- Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.